Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses during a Large Outbreak in Northern Nigeria

ABSTRACT Since 2005, a large poliomyelitis outbreak associated with type 2 circulating vaccine-derived poliovirus (cVDPV2) has occurred in northern Nigeria, where immunization coverage with trivalent oral poliovirus vaccine (tOPV) has been low. Phylogenetic analysis of P1/capsid region sequences of isolates from each of the 403 cases reported in 2005 to 2011 resolved the outbreak into 23 independent type 2 vaccine-derived poliovirus (VDPV2) emergences, at least 7 of which established circulating lineage groups. Virus from one emergence (lineage group 2005-8; 361 isolates) was estimated to have circulated for over 6 years. The population of the major cVDPV2 lineage group expanded rapidly in early 2009, fell sharply after two tOPV rounds in mid-2009, and gradually expanded again through 2011. The two major determinants of attenuation of the Sabin 2 oral poliovirus vaccine strain (A481 in the 5′-untranslated region [5′-UTR] and VP1-Ile143) had been replaced in all VDPV2 isolates; most A481 5′-UTR replacements occurred by recombination with other enteroviruses. cVDPV2 isolates representing different lineage groups had biological properties indistinguishable from those of wild polioviruses, including efficient growth in neuron-derived HEK293 cells, the capacity to cause paralytic disease in both humans and PVR-Tg21 transgenic mice, loss of the temperature-sensitive phenotype, and the capacity for sustained person-to-person transmission. We estimate from the poliomyelitis case count and the paralytic case-to-infection ratio for type 2 wild poliovirus infections that ∼700,000 cVDPV2 infections have occurred during the outbreak. The detection of multiple concurrent cVDPV2 outbreaks in northern Nigeria highlights the risks of cVDPV emergence accompanying tOPV use at low rates of coverage in developing countries.

[1]  F. Mahoney,et al.  Progress toward poliomyelitis eradication in Nigeria. , 2014, The Journal of infectious diseases.

[2]  S. Plotkin,et al.  27 – Poliovirus vaccine—inactivated , 2013 .

[3]  R. Sutter,et al.  28 – Poliovirus vaccine—live , 2013 .

[4]  Meeting of the Strategic Advisory Group of Experts on immunization, April 2012--conclusions and recommendations. , 2016, Releve epidemiologique hebdomadaire.

[5]  M. Suchard,et al.  Bayesian Phylogenetics with BEAUti and the BEAST 1.7 , 2012, Molecular biology and evolution.

[6]  Daniel L. Ayres,et al.  BEAGLE: An Application Programming Interface and High-Performance Computing Library for Statistical Phylogenetics , 2011, Systematic biology.

[7]  Progress towards global interruption of wild poliovirus transmission, January 2011-March 2012. , 2012, Releve epidemiologique hebdomadaire.

[8]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[9]  D. Filman,et al.  An Externalized Polypeptide Partitions between Two Distinct Sites on Genome-Released Poliovirus Particles , 2011, Journal of Virology.

[10]  M. Pate,et al.  Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population , 2011, The Journal of infectious diseases.

[11]  Marc A Suchard,et al.  A Bayesian phylogenetic method to estimate unknown sequence ages. , 2011, Molecular biology and evolution.

[12]  Progress in interrupting wild poliovirus circulation in countries with re-established transmission:Africa, 2009–2010. , 2011, Releve epidemiologique hebdomadaire.

[13]  Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. , 2011, MMWR. Morbidity and mortality weekly report.

[14]  R. Sutter,et al.  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial , 2010, The Lancet.

[15]  N. Nathanson,et al.  From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed , 2010, American journal of epidemiology.

[16]  Who Publication Polio vaccines and polio immunization in the pre-eradication era: WHO position paper--recommendations. , 2010, Vaccine.

[17]  W. Liu,et al.  Emergence and Localized Circulation of a Vaccine-Derived Poliovirus in an Isolated Mountain Community in Guangxi, China , 2010, Journal of Clinical Microbiology.

[18]  J. Corander,et al.  Implications of a circulating vaccine-derived poliovirus in Nigeria. , 2010, The New England journal of medicine.

[19]  Meeting of the Strategic Advisory Group of Experts on immunization, October 2009--Conclusions and recommendations. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[20]  Progress towards eradicating poliomyelitis in Nigeria, January 2009- June 2010. , 2010, Releve epidemiologique hebdomadaire.

[21]  Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. , 2010, Releve epidemiologique hebdomadaire.

[22]  J. van de Kassteele,et al.  Shedding of Vaccine Viruses with Increased Antigenic and Genetic Divergence after Vaccination of Newborns with Monovalent Type 1 Oral Poliovirus Vaccine , 2009, Journal of Virology.

[23]  Claire Blanchard,et al.  Recombination between Polioviruses and Co-Circulating Coxsackie A Viruses: Role in the Emergence of Pathogenic Vaccine-Derived Polioviruses , 2009, PLoS pathogens.

[24]  A. Vincent,et al.  Rapid Group-, Serotype-, and Vaccine Strain-Specific Identification of Poliovirus Isolates by Real-Time Reverse Transcription-PCR Using Degenerate Primers and Probes Containing Deoxyinosine Residues , 2009, Journal of Clinical Microbiology.

[25]  G. I. Div Wild poliovirus type 1 and type 3 importations - 15 countries, Africa, 2008-2009. , 2009 .

[26]  Laboratory surveillance for wild and vaccine-derived polioviruses - worldwide, January 2008-June 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[27]  W. Roper,et al.  Wild poliovirus type 1 and type 3 importations--15 countries, Africa, 2008-2009. , 2009, MMWR. Morbidity and mortality weekly report.

[28]  P. Fine,et al.  Estimating the Extent of Vaccine-Derived Poliovirus Infection , 2008, PloS one.

[29]  Javier Martin,et al.  Changes in Population Dynamics during Long-Term Evolution of Sabin Type 1 Poliovirus in an Immunodeficient Patient , 2008, Journal of Virology.

[30]  M. Birmingham,et al.  Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. , 2008, The Journal of infectious diseases.

[31]  O. Kew,et al.  Calibration of Multiple Poliovirus Molecular Clocks Covering an Extended Evolutionary Range , 2008, Journal of Virology.

[32]  M. Pallansch,et al.  A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005. , 2008, The Journal of infectious diseases.

[33]  R. Sutter,et al.  Poliovirus vaccine-live , 2008 .

[34]  Progress towards eradicating poliomyelitis in Nigeria, January 2007-August 2008. , 2008, Releve epidemiologique hebdomadaire.

[35]  M. Pallansch,et al.  Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. , 2007, Virus research.

[36]  Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2006-June 2007. , 2007, MMWR. Morbidity and mortality weekly report.

[37]  Kimberly M Thompson,et al.  Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication , 2006, Risk analysis : an official publication of the Society for Risk Analysis.

[38]  J. Meredith,et al.  Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication , 2006, Journal of Virology.

[39]  Wenbo Xu,et al.  An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. , 2006, The Journal of infectious diseases.

[40]  A. Vincent,et al.  Modulation of Poliovirus Replicative Fitness in HeLa Cells by Deoptimization of Synonymous Codon Usage in the Capsid Region , 2006, Journal of Virology.

[41]  J. Gerberding,et al.  Resurgence of wild poliovirus type 1 transmission and consequences of importation--21 countries, 2002-2005. , 2006, MMWR. Morbidity and mortality weekly report.

[42]  M. Pallansch,et al.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.

[43]  E. Dobrikova,et al.  Genetic Determinants of Cell Type-Specific Poliovirus Propagation in HEK 293 Cells , 2005, Journal of Virology.

[44]  O. Pybus,et al.  Bayesian coalescent inference of past population dynamics from molecular sequences. , 2005, Molecular biology and evolution.

[45]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[46]  Progress towards poliomyelitis eradication in Nigeria, January 2004-July 2005. , 2005, Releve epidemiologique hebdomadaire.

[47]  Lilly Yuen,et al.  Circulation of Type 1 Vaccine-Derived Poliovirus in the Philippines in 2001 , 2004, Journal of Virology.

[48]  M. Pallansch,et al.  Multiplex PCR Method for Identifying Recombinant Vaccine-Related Polioviruses , 2004, Journal of Clinical Microbiology.

[49]  D. Pillay,et al.  Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man , 2004, The Lancet.

[50]  M. Pallansch,et al.  Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. , 2003, The Journal of infectious diseases.

[51]  V. Agol,et al.  Retrospective Analysis of a Local Cessation of Vaccination against Poliomyelitis: a Possible Scenario for the Future , 2003, Journal of Virology.

[52]  M. Pallansch,et al.  Serial Recombination during Circulation of Type 1 Wild-Vaccine Recombinant Polioviruses in China , 2003, Journal of Virology.

[53]  Mark A. Pallansch,et al.  Complete Genomic Sequencing Shows that Polioviruses and Members of Human Enterovirus Species C Are Closely Related in the Noncapsid Coding Region , 2003, Journal of Virology.

[54]  John P. Huelsenbeck,et al.  MrBayes 3: Bayesian phylogenetic inference under mixed models , 2003, Bioinform..

[55]  M. Pallansch,et al.  Circulation of Endemic Type 2 Vaccine-Derived Poliovirus in Egypt from 1983 to 1993 , 2003, Journal of Virology.

[56]  D. Rousset,et al.  Recombinant Vaccine–Derived Poliovirus in Madagascar , 2003, Emerging infectious diseases.

[57]  Genetic recombination in wild-type poliovirus. , 2002, The Journal of general virology.

[58]  Gerry Shaw,et al.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  M. Pallansch,et al.  Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus , 2002, Science.

[60]  P. Minor,et al.  Poliovirus Vaccines: Molecular Biology and Immune Response , 2002 .

[61]  Apparent global interruption of wild poliovirus type 2 transmission. , 2001, MMWR. Morbidity and mortality weekly report.

[62]  M. Pallansch,et al.  Molecular Evolution of a Type 1 Wild-Vaccine Poliovirus Recombinant during Widespread Circulation in China , 2000, Journal of Virology.

[63]  S. Guillot,et al.  Natural Genetic Exchanges between Vaccine and Wild Poliovirus Strains in Humans , 2000, Journal of Virology.

[64]  V. Agol,et al.  Evolution of Circulating Wild Poliovirus and of Vaccine-Derived Poliovirus in an Immunodeficient Patient: a Unifying Model , 2000, Journal of Virology.

[65]  Javier Martin,et al.  Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion , 2000, Journal of Virology.

[66]  Z. Grossman,et al.  Resolution of the Pathways of Poliovirus Type 1 Transmission during an Outbreak , 2000, Journal of Clinical Microbiology.

[67]  L. Fan,et al.  Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype. , 1999, Virology.

[68]  P. McIntyre,et al.  Vaccine-associated paralytic poliomyelitis. , 1999, Communicable diseases intelligence.

[69]  M. Pallansch,et al.  Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient , 1998, Journal of Clinical Microbiology.

[70]  M. Pallansch,et al.  Serotype-Specific Identification of Polioviruses by PCR Using Primers Containing Mixed-Base or Deoxyinosine Residues at Positions of Codon Degeneracy , 1996, Journal of Clinical Microbiology.

[71]  David Posada,et al.  MODELTEST: testing the model of DNA substitution , 1998, Bioinform..

[72]  M. Pallansch,et al.  Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. , 1997, The Journal of infectious diseases.

[73]  F. Forastiere,et al.  Unimmunized Gypsy populations and implications for the eradication of poliomyelitis in Europe. , 1997, The Journal of infectious diseases.

[74]  M. Pallansch,et al.  Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy , 1996, Journal of clinical microbiology.

[75]  M. Pallansch,et al.  Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. , 1996, JAMA.

[76]  M. Pallansch,et al.  Comparative study of five methods for intratypic differentiation of polioviruses , 1995, Journal of clinical microbiology.

[77]  M. Mulders,et al.  Isolation of epidemic poliovirus from sewage during the 1992–3 type 3 outbreak in the Netherlands , 1995, Epidemiology and Infection.

[78]  J. Modlin,et al.  Vaccine-Associated Paralytic Poliomyelitis , 1994, Journal of child neurology.

[79]  T. Hovi,et al.  Selective isolation of poliovirus in recombinant murine cell line expressing the human poliovirus receptor gene , 1994, Journal of clinical microbiology.

[80]  P. Minor,et al.  Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. , 1993, Journal of virological methods.

[81]  S. R. Pollard,et al.  Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. , 1993, Virology.

[82]  M. Pallansch,et al.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  S. R. Pollard,et al.  The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. , 1991, Virology.

[84]  R. Ren,et al.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus , 1991, Journal of virology.

[85]  H. Yonekawa,et al.  Transgenic mice susceptible to poliovirus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[86]  G. Schild,et al.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine , 1989, Journal of virology.

[87]  G. Dunn,et al.  Intertypic genomic rearrangements of poliovirus strains in vaccinees. , 1988, Virology.

[88]  L. Schonberger,et al.  Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. , 1987, JAMA.

[89]  D. Filman,et al.  Three-dimensional structure of poliovirus at 2.9 A resolution. , 1985, Science.

[90]  A. Nomoto,et al.  Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. , 1984, Journal of molecular biology.

[91]  J. Kingman On the genealogy of large populations , 1982, Journal of Applied Probability.

[92]  J. Mcgowan,et al.  Vaccine-associated poliomyelitis in the United States, 1961-1972. , 1976, American journal of epidemiology.

[93]  A. Sabin,et al.  History of Sabin attenuated poliovirus oral live vaccine strains , 1973 .

[94]  J. Melnick,et al.  Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. , 1967, American journal of epidemiology.

[95]  A. Langmuir,et al.  PARALYTIC DISEASE ASSOCIATED WITH ORAL POLIO VACCINES. , 1964, JAMA.